Royalty Pharma has secured a synthetic royalty deal with Ferring Pharmaceuticals for the gene therapy adstiladrin (nadofaragene firadenovec-vncg). The agreement involves an initial payment of $300 million, granting Royalty Pharma a 5.1% royalty on the net sales of the treatment in the US. An additional milestone payment of $200 million hinges on achieving certain manufacturing goals by 2025. Once this milestone is reached, the royalty rate will increase to 8.0%. Nadofaragene is an FDA-approved intravesical gene therapy designed for high-risk Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. The therapy transforms bladder wall cells into interferon microfactories, bolstering the body’s defences against cancer.
Global News and Digital Insights
for the Healthcare Industry
Menu
